Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
HER2
Jiangsu Alphamab Biopharmaceuticals Partners with Shanghai Jinmant Biotech for JSKN003 ADC
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced that its wholly-owned...
Alphamab Oncology Strikes Licensing Deal with CSPC Pharma for HER2 Targeted ADC in China
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a licensing...
FDA Panel Weighs in on Narrowing Use of PD-1 Inhibitors in Stomach and Esophageal Cancers
The U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) convened on September 26 to scrutinize the...
Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment
FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...
Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy
Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...
NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS
The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with...
AstraZeneca’s AKT Inhibitor Truqap Misses Primary Endpoints in Phase III TNBC Trial
AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has encountered a setback in the Phase...
BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US
BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...
RemeGen’s Disitamab Vedotin Shows Positive Results in Phase III Trial for HER2 Positive Breast Cancer
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced positive results from...
Astellas Resubmits FDA Application for Vyloy as Treatment for CLDN18.2-Positive Cancer
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has resubmitted its first-in-class anti-CLDN18.2 biologic...
Huadong Medicine’s EGFR Inhibitor Mefatinib for NSCLC Accepted by NMPA for Review
Huadong Medicine Co., Ltd (SHE: 000963), a leading pharmaceutical company based in China, has announced...
Betta Pharmaceuticals Files for Market Approval of CDK4/6 Inhibitor BPI-16350 in China
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...
Henlius’ HER2 Dual-Targeted Therapy Gets Green Light for Global Phase III Trial by FDA
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced that it has received approval from...
US FDA Greenlights Henlius Biotech’s Hanquyou as Biosimilar to Roche’s Herceptin
Shanghai Henlius Biotech Inc. (HKG: 2696) has achieved a significant milestone with the US Food...
Guangzhou LBP Earns NMPA Nod for HER2 Detection Reagent to Guide Breast Cancer Treatment
Guangzhou LBP Medicine Science & Technology Co., Ltd (SHA: 688393), a biopharmaceutical company based in...
Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023
Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing...
Sanofi Explores Sale of Amunix Pharmaceuticals as It Shifts Focus to Immunology
Sanofi (NASDAQ: SNY), the France-based pharmaceutical giant, is reportedly in talks with potential buyers for...
Enhertu Shows 58.3% Response Rate in Phase II Lung Cancer Study, AstraZeneca and Daiichi Sankyo Report
The Phase II DESTINY-Lung05 study results for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate co-developed by...